how much can we adapt? an eortc perspective saskia litière eortc - biostatistician
TRANSCRIPT
![Page 1: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/1.jpg)
How much can we adapt?An EORTC perspective
Saskia Litière
EORTC - Biostatistician
![Page 2: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/2.jpg)
I have no conflicts of interest
2
![Page 3: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/3.jpg)
Adaptive designs• What?• Why?• The challenges• Examples
Currently part of EORTC portfolio Currently not (yet) part of EORTC portfolio
• Take home messages
Outline
3
![Page 4: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/4.jpg)
“… a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and
hypotheses based on analysis of data (usually interim data) from subjects in the study. “
What is an adaptive design?
4
![Page 5: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/5.jpg)
• They aim to make efficient use of patient and financial resources
• Allow for real-time learning during the course of a trial
• Relatively flexible: modifications possible in the course of trial which make the approach more robust to failure
• The drug development process is streamlined and optimized
Why use adaptive designs?
5
![Page 6: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/6.jpg)
• To control the
operating characteristics
• To control the bias due to the adaptation Statistical Operational
• To guarantee that the results can
be interpreted and explained!
The challenges
6
![Page 7: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/7.jpg)
• Early stopping for futility and/or efficacy
• Drop treatment arm(s) – also known as pick the winner designs
• Biomarker adaptive designs
• Sample size re-estimation• Adaptive randomization…
To name but a few …
Several possible approaches
7
Well-known
Less understood
![Page 8: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/8.jpg)
Most of them come down to
8
Learn Confirm
One trial
Change H0? Change design parameters?
![Page 9: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/9.jpg)
A few examples
9
![Page 10: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/10.jpg)
EORTC 62012 in first line treatment of advanced, high grade STS
10
R
Doxorubicin
Doxorubicin + Ifosfamide In
terim
1: P
FS?
Group sequential design
Inte
rim 2
: OS?
Fina
l: O
S?
![Page 11: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/11.jpg)
TRUSTS (EORTC 62091) in advanced or metastatic STS
11
R
Trabectedin 1.5 mg/m2 24-h
Doxorubicin 75 mg/m2
Doxo 75 mg/m2
T 3-h or 24-h
Sele
ct th
e be
stPF
S
Phase IIb3 x 40 pts
Phase III2 x 110 pts
Trabectedin 1.3 mg/m2 3-h
PFS?
Seamless phase II/III design
![Page 12: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/12.jpg)
– Both steps are conducted independently and the results of both steps are combined in the end in an overall test result
– Shortens time and patient exposure– Relatively flexible – Efficient use of patient resources
– Complex design: statistics are difficult to explain– Gap in accrual between phase II and phase III– Logistically challenging– Difficult in studies with long-term endpoints
» Unless in combination with a short-term endpoint for the phase II part … another long and complex story on type I error and correlation
12
TRUSTS (EORTC 62091) in advanced or metastatic STS
![Page 13: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/13.jpg)
13
Cytel Webinar for East®SurvAdapt, October 28, 2010
2-sided = a5%Power = 90%HR = 0.7
Sample size re-estimation
![Page 14: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/14.jpg)
• May increase the risk of running an enlarged negative trial
• Possibility of second guessing A resampling decision can be easily interpreted
as “the treatment is not as efficient as expected”
→ Operational bias? Accrual?
→ May require extensive (expensive) logistics
Protection of study integrity is essential!
Sample size re-estimation
14
![Page 15: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/15.jpg)
Battle Trial – Adaptive randomization
Lee et al.Zhou et al. CT 2008
![Page 16: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/16.jpg)
Prior probability of
each treatment
success given marker
8-week outcome observed
Probabilities of treatment
success updated based
on observed results
Maximizes the chance that the patient receives the treatment that is most effective for him/her
Battle Trial – Adaptive randomization
Randomizeusing the weights given by prior prob
![Page 17: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/17.jpg)
• Sample size?• Requires fast dataflow – logistically demanding
especially in large multicenter trials• Does not work for long-term endpoint. • Difficult to interpret results beyond estimation
Comparisons? Precision?
• Recruitment patterns can change during the course of the trial because of deduced knowledge of randomization probabilities
17
Adaptive randomization
![Page 18: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/18.jpg)
• Simulations suggest very similar operational characteristics may be achieved if applying classical 2-stage designs with stopping rules Korn and Freidlin, JCO 2011 Yuan and Yin, JCO 2011
• Example of such an alternative: CREATE (EORTC 90101) A Simon 2-stage design is being used to assess
the activity of Crizotinib in each of 6 cohorts of patients (ALK/MET+)
18
Adaptive randomization
![Page 19: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/19.jpg)
• The STBSG EORTC is more adaptive than you may have thought
• There are challenging times ahead, both for clinicians as well as statisticians Flexible design strategies More efficient use of resources
• While the sky seems to be the limit, experience teaches us to be wary and critical of solutions presented as ‘miracles’.
Conclusion
19
![Page 20: How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician](https://reader031.vdocuments.site/reader031/viewer/2022032107/56649eb55503460f94bbd7ee/html5/thumbnails/20.jpg)
Stats colleagues at the EORTC, specifically
Acknowledgment
20
Laurence Collette Jan Bogaerts Murielle Mauer